Speakers will include:
David Rimm, MD, Ph.D., Yale University School of Medicine
Karen Leroy, MD, Ph.D., Universite Paris Descartes
Joseph Beechem Ph.D., NanoString Technologies

Below are a subset of abstracts that best illustrate the unique capabilities of NanoString’s technology platform. A complete list of 51 NanoString-enabled abstracts follows.

Digital Spatial Profiling
Title: Highly multiplexed analysis of immune cell subsets in non-small cell lung cancer: validation of protein and RNA analysis by the NanoString DSP platform
Date/Time: Monday, April 16 2018, 1pm-5:00pm CT
Author: James Zai, Genentech
Poster #/Location: 2089/Poster Section 4, Board 4
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/1925
Digital Spatial Profiling (DSP) shows high section to section reproducibility and correlation with flow cytometry and immunohistochemistry.

Title: Digital spatial profiling platform allows for spatially-resolved, high-plex quantification of mRNA distribution and abundance on FFPE and fresh frozen tissue sections
Date/Time: Tuesday, April 17 2018, 8am-12:00pm CT
Author: Daniel Zollinger, NanoString
Poster #/Location: 3434/Section 18, Board 16
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7119
Digital Spatial Profiling can be used to obtain high-plex, spatial mRNA expression data (10’s to 100’s of genes) and protein expression data on FFPE and fresh frozen tissue sections. 

Title: High-plex immune marker spatial profiling quantitation by NanoString® Digital Spatial Profiling technology and quantitative immunofluorescence
Date/Time: Tuesday, April 17, 2018, 8am-12:00pm CT
Author: Maria I. Toki, Yale University Medical Center
Poster #/Location: 3621/Section 25, Board 29
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/2962
Digital Spatial Profiling shows promise in a pilot study of 30 spatially resolved protein immune markers for prognostic significance in a EGFR TKI treated NSCLC cohort as well as an ITx treated Melanoma cohort, and high concordance with AQUA. A Quantitative Immunofluoresence Assay (AQUA™) is a method for quantifying proteins through immunofluorescence.

Title: Validation of Digital Spatial Profiling of Key Immuno-Oncology Targets for Mouse FFPE Preclinical Models
Date/Time: Tuesday, April 17, 8:00am-12:00pm CT
Author: Sarah Warren, Ph.D., NanoString
Poster #/Location: 3858/Section 36, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/3493
Digital Spatial Profiling allows for the multiplexing of 10s to 100s of proteins, and NanoString has validated an antibody panel designed to characterize key tumor and immunology markers for FFPE samples from mouse preclinical models.

PlexSet Abstracts
Title: Digital Gene Expression of up to 96 Targets in 96 Samples for Cell Line Screening with nCounter® PlexSet
Date/Time: Monday, April 16 2018, 1pm-5:00pm CT
Author: Giang T. Ong, NanoString
Poster #/Location: 2342/Section 16, Board 3
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7033
NanoString demonstrates that the nCounter Analysis System can detect gene expression in 96 genes for 96 samples in parallel from cell lysate using the lyse-and-go protocol and PlexSet panel. The data correlates well with purified total RNA and is an efficient solution for cell line screening studies.

Title: Cross-Comparison of Targeted Gene Expression Technologies for Patient Stratification
Date/Time: Tuesday, April 17 2018, 8:00am-12:00pm CT
Author: R. Venkatramanan et al, Covance
Poster #/Location: 3418/Section 16, Board 3
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7089
A comparison of PlexSet technology with various qPCR technologies on 96 colorectal FFPE samples. PlexSet, showed high correlation with RNA seq and robust reproducibility.

Gene Expression Profiling
Title: The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort
Date/Time: Tuesday, April 17, 2018, 1:00pm-5:00pm CT
Author: D. Damotte, et al, Univ. Paris Descartes APHP and INSERM
Poster #/Location: 4546/Section 25, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7648
The tumor inflammation signature (TIS) and other gene expression signatures, simultaneously analyzed using the IO 360 panel, predict clinical benefit of anti-PD1 treatment (nivolumab and pembrolizumab) in ‘real life’ patients with various cancer types, including NSCLC.

Title: Infiltrating immune cells in breast cancer subtypes
Date/Time: Tuesday, April 17 2018, 8:00am-12:00pm CT
Author: J.L. Matta et al, Ponce Health Sciences Institute and H. Lee Moffitt Cancer Center
Poster #/Location: 5698/Section 32, Board 4
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977
Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapeutics.

Title: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab 
Date/Time: Tuesday, April 17 2018, 1:00pm-5:00pm CT
Author: A. Waks et al, Dana Farber Cancer Institute
Poster #/Location: 4565/Section 26, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7859
HR+/HER2- breast tumors with higher levels of tumor immune activity have a more favorable response to chemo plus bevacizumab. Deeper analysis into NanoString signatures show the underlying biological mechanisms of this observation: T-cell and checkpoint-related biomarkers decrease and chemokines and complement pathway genes increase following treatment.

Title: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma
Date/Time: Sunday, April 15, 2018, 1:00pm-5:00pm
Author: M. Capone et al, A. Waks et al, Istituto Nazionale Tumori IRCCS Fondazione
Poster #/Location: 558/Section 25, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/2941
The NanoString IO 360 Panel is used to characterize tumor and PMBC samples from patients with metastatic melanoma treated with either ipilimumab or pembrolizumab to characterize local and peripheral patterns of gene expression associated with clinical benefit of therapy.

Title: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms
Date/Time: Tuesday, April 17, 2018, 1:00pm-5:00pm CT
Author: R. Novosiadly et al, Eli Lilly & Co
Poster #/Location: 4549/Section 25, Board 4
Pemetrexed promotes intra–tumor T cell–mediated immune response through immunogenic tumor cell death and increased activation and metabolic fitness of T cells, leading to an enhanced anti–tumor efficacy in combination with a PD–L1 antibody as shown by using NanoString for gene expression analysis of syngeneic tumor models.

Title: Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study
Date/Time: Monday, April 16, 2018, 1:00pm-5:00pm
Author: A. Naing, et al, MD Anderson and Neon Therapeutics
Poster #/Location: LB-147/Section 43, Board 14